Recent Business Highlights
Biologics: Maximizing value of current assets in near to mid-term while
pursuing global development
BIOLOGICS REVENUE HAS GROWN AT APPROX.
30% CAGR OVER THE LAST 10 YEARS
EU/US approval enabling studies initiated
for pegfilgrastim
Rituximab and bevacizumab approval
enabling studies for EU/US expected to be
initiated in next 4 - 6 quarters
2 new molecules entering clinical
development in next 12 months
1
Grafeel®
Dr. Reddy's filgrastim
launched; The 1st
biosimilar filgrastim
(G-CSF) in India
2 RedituxⓇ
Dr. Reddy's rituximab
launched in India; 1st
biosimilar MAb in
the world
3
CrespⓇ
Dr. Reddy's
darbepoetin alfa was
launched in India;
The first biosimilar
darbepoetin alfa in
the world
4 Peg-grafeel®
Dr. Reddy's peg
filgrastim launched;
End-to-end
development in-
house (single
source
pegfilgrastim)
EU/US Clinical
programs initiated
for rituximab and
pegfilgrastim
2014
Pre-2006
2007
Above diagram depicts calendar years
2012
2016
2017
EM clinical Studies for
trastuzumab and bevacizumab
EU/US Clinical Program
initiated for bevacizumab
MERCK
SERONO
Fresenius Kabi
bought Merck KGaA's
Biosimilar business
in Sept 17
"
2011
2010
Dr. Reddy's
20
20View entire presentation